Company intelligence / Profile preview

PlenOptika

Cambridge, Massachusetts, United Statesplenoptika.com ↗

Ownership: Private
Development stage: Commercial

Overview

PlenOptika’s QuickSee devices have been validated in over twenty IRB-based clinical studies across eight countries with more than two thousand patients. Clinical results show that prescriptions derived from QuickSee measurements are accepted by patients at rates equivalent to those from gold-standard subjective refraction. The devices have demonstrated high accuracy in both adult and pediatric populations, improving access to vision correction globally.

Therapeutic areas: Ophthalmology
Modalities: Device (Handheld autorefractor/keratometer)Non-pharmacological therapy (vision diagnostics)
Industry: Physiological Monitoring

Partnerships

New England College of OptometryInternational Agency for the Prevention of Blindness (IAPB)NASA / Translational Research Institute for Space Health (TRISH)

Beyond the preview

Go deeper on PlenOptika.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PlenOptika.

Explore the full profile